Medicare Enrolled
Dr. Saeid Safaee, MD
Pulmonary Disease · Glendale, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Safaee from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Safaee?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Safaee
Dr. Saeid Safaee is a pulmonary disease specialist in Glendale, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Safaee performed 6,289 Medicare services across 3,208 unique beneficiaries.
Between the years covered by Open Payments, Dr. Safaee received a total of $8,302 from 43 pharmaceutical and/or device companies across 352 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Safaee is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 3% volume in CA
$8,302 industry payments
Medicare Practice Summary
Medicare Utilization ↗6,289
Medicare services
Top 3% in CA for pulmonary disease
3,208
Unique beneficiaries
$78
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~331 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
1,852 | $67 | $250 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
1,442 | $101 | $350 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
503 | $108 | $175 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
457 | $147 | $550 |
| Breathing device use evaluation An assessment of how a patient uses a breathing device. The provider reviews the patient's technique and device handling. |
278 | $16 | $65 |
| Inhaled albuterol and ipratropium bromide via DME Administration of FDA-approved albuterol and ipratropium bromide medication through durable medical equipment. |
274 | $0 | $25 |
| Spirometry test before and after medication A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication. |
273 | $35 | $200 |
| Inhalation treatment for airway obstruction or sputum production A treatment involving the inhalation of medication to help clear airway obstructions or reduce sputum production. |
273 | $8 | $100 |
| Lung volume test using sensors A test that measures the amount of air in the lungs using sensors. |
273 | $49 | $200 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
273 | $52 | $200 |
| Critical care, first 30-74 min Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient. |
250 | $177 | $462 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
69 | $139 | $300 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
45 | $76 | $150 |
| Ultrasound guidance for blood vessel access Use of ultrasound imaging to help locate and access a blood vessel. This guidance assists healthcare providers in performing procedures such as inserting IV lines or drawing blood. |
14 | $12 | $103 |
| Insertion of non-tunneled central venous catheter A procedure to place a central venous catheter for infusion in patients aged 5 years or older. The catheter is inserted directly into a large vein without being tunneled under the skin. |
13 | $69 | $212 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
0.2% high complexity
0.2% medium
99.6% routine
Industry Payment Transparency
Open Payments through 2024 ↗$8,302
Total received (2018-2024)
Avg $1,186/year across 7 years
Top 19% in CA for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
43
Companies
352
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$8,277 (99.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$25 (0.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,159
2023
$948
2022
$813
2021
$804
2020
$616
2019
$1,520
2018
$2,442
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
GlaxoSmithKline, LLC.
$312
Pulmonx Corporation
$160
Insmed, Inc.
$112
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$100
GENZYME CORPORATION
$76
Merck Sharp & Dohme LLC
$73
Mylan Specialty L.P.
$51
Regeneron Healthcare Solutions, Inc.
$50
Galvanize Therapeutics, Inc
$37
United Therapeutics Corporation
$33
Baxter Healthcare
$31
INTUITIVE SURGICAL, INC.
$28
Optinose US, Inc.
$26
Grifols USA, LLC
$25
AstraZeneca Pharmaceuticals LP
$24
Boehringer Ingelheim Pharmaceuticals, Inc.
$22
Top 3 companies account for 50.4% of 2024 payments
All-time payments by company (2018-2024) ›
GlaxoSmithKline, LLC.
$1,925
Boehringer Ingelheim Pharmaceuticals, Inc.
$1,014
Veran Medical Technologies, Inc.
$1,002
AstraZeneca Pharmaceuticals LP
$559
Grifols USA, LLC
$288
Actelion Pharmaceuticals US, Inc.
$265
Allergan Inc.
$250
Pulmonx Corporation
$241
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$223
Philips Electronics North America Corporation
$201
GENZYME CORPORATION
$196
Mylan Specialty L.P.
$170
Regeneron Healthcare Solutions, Inc.
$157
Merck Sharp & Dohme Corporation
$138
Merck Sharp & Dohme LLC
$136
PFIZER INC.
$134
United Therapeutics Corporation
$130
Abbott Laboratories
$130
Insmed, Inc.
$112
Baxter Healthcare
$90
Sunovion Pharmaceuticals Inc.
$89
E.R. Squibb & Sons, L.L.C.
$82
Bayer HealthCare Pharmaceuticals Inc.
$77
AbbVie Inc.
$73
Gilead Sciences, Inc.
$67
Janssen Pharmaceuticals, Inc
$63
ABBVIE INC.
$47
ABIOMED
$47
Genentech USA, Inc.
$46
Galvanize Therapeutics, Inc
$37
Allergan, Inc.
$31
La Jolla Pharmaceutical Company
$28
INTUITIVE SURGICAL, INC.
$28
Optinose US, Inc.
$26
Tactile Systems Technology Inc
$26
Becton, Dickinson and Company
$26
Inspire Medical Systems, Inc.
$25
CSL Behring
$25
Otsuka America Pharmaceutical, Inc.
$23
Theravance Biopharma, Inc.
$21
Teva Pharmaceuticals USA, Inc.
$20
Horizon Therapeutics plc
$17
Circassia Pharmaceuticals Inc
$16
Top 3 companies account for 47.5% of all-time payments
Associated products mentioned in payments ›
(8874) inCourage · AIRSUPRA · ALIYA SYSTEM · AMPLATZER Occluders · ANORO · ANORO ELLIPTA · AVYCAZ · Adempas · AirDuo Digihaler · Arikayce · BEVESPI AEROSPHERE · BREO · BREO ELLIPTA · BREZTRI · CHARTIS CATHETER · DALVANCE · DUPIXENT · Da Vinci Surgical System · ELIQUIS · Esbriet · FASENRA · Flexitouch Plus · GIAPREZA · Hillrom - Vest System Model 105 Home Care · INSPIRE · Impella · LOKELMA · LONHALA MAGNAIR · LifeVest · NUCALA · OFEV · OPSUMIT · OPSUMIT MACITENTAN · ORENITRAM · Prolastin-C Liquid · RAYOS · Respiratoriy Care Undiv · SAMSCA · STIOLTO · STIOLTO RESPIMAT · SYMBICORT · Spin · TEFLARO · TRELEGY ELLIPTA · TUDORZA PRESSAIR · TYVASO · Trilogy 100 · UPTRAVI · Utibron · VERQUVO · VIBATIV · WINREVAIR · Wellcentive Undiv · XARELTO · Xhance · YUPELRI · Yupelri · ZEPHYR DELIVERY CATHETER · ZERBAXA · Zemaira · inCourage
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Pulmonary diseases within 10 mi
244
Per 100K population
2.5
County median income
$87,760
Nearest hospital
GLENDALE MEM HOSPITAL & HLTH CENTER
2.9 mi
2.9 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Safaee is a mixed practice specialist, with above-average Medicare volume (top 3% in CA), with low-engagement industry engagement in the top 19% of CA peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Safaee experienced with hospital follow-up visit, moderate complexity?
Based on Medicare claims data, Dr. Safaee performed 1,852 hospital follow-up visit, moderate complexity services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Safaee receive payments from pharmaceutical companies?
Yes. Dr. Safaee received a total of $8,302 from 43 companies across 352 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Safaee's costs compare to other pulmonary diseases in Glendale?
Dr. Safaee's average Medicare payment per service is $78. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Safaee) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Glendale
Browse pulmonary diseases in Glendale ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in CA
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in CA
Which CA pulmonary diseases receive the most from drug and device companies.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc.
By company
Veran Medical Technologies, Inc. Payments to Doctors
See all physicians who received payments from Veran Medical Technologies, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology